Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesSalix Pharmaceuticals Announces Statistically Significant Results for Both the Primary and Key Secondary Analyses of Rifaximin in the Treatment of Non–Constipation Irritable Bowel Syndrome in Two Phase 3 Trials
Salix Pharmaceuticals, 09/15/09
Salix Pharmaceuticals, Ltd. announced the successful outcome of two Phase 3, randomized, double–blind, placebo–controlled, multicenter trials, TARGET 1 and TARGET 2, designed to evaluate the efficacy and safety of rifaximin 550 mg TID in the treatment of patients with non–constipation irritable bowel syndrome. In each trial rifaximin versus placebo treated patients demonstrated a statistically significant improvement for the primary endpoint of the adequate relief of IBS symptoms as assessed over one month following completion of a 14–day course of therapy.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
A Clinical Review of Echinocandins in Pediatric Patients
Annals of Pharmacotherapy, 12/16/09
Sanofi Pasteur expands study of vaccine against Clostridium difficile into the U.S.
Sanofi-aventis, 12/15/09
Second Pivotal Phase III Study of Gileads Darusentan for Resistant Hypertension Misses Primary Endpoints
Gilead, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor